X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.2217
-0.0147 (-6.22%)
Apr 1, 2025, 4:00 PM EDT - Market closed
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 143 employees as of December 31, 2024. The number of employees increased by 50 or 53.76% compared to the previous year.
Employees
143
Change (1Y)
50
Growth (1Y)
53.76%
Revenue / Employee
$17,881
Profits / Employee
-$261,888
Market Cap
38.50M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
XFOR News
- 7 days ago - X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025 - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - GlobeNewsWire